After years of conducting clinical trials using cutting-edge drugs with the potential to effectively treat obesity, it’s clear that the pursuit of the ideal obesity treatment remains a complex challenge. This complexity is rooted in the multifaceted nature of obesity, influenced by a combination of environmental and genetic factors. While a ‘miracle pill’ for obesity remains elusive, significant strides have been made in the field of treatment.

One noteworthy advancement is the synergy of breakthroughs in neuro-pharmacology and the adoption of diet acceptance behavioral therapy (DABT). This combined approach has emerged as one of the most effective methods for treating obesity, offering a high success rate for long-term weight loss.

Our involvement in ongoing clinical trials continues to shed light on the remarkable potential of these innovative treatments. Subjects receiving injections of GLP-1 agonists have experienced substantial weight loss, reducing their body weight by up to 12 percent. Additionally, diabetic subjects have seen noteworthy improvements in their baseline HgbA1c levels.

One intriguing aspect of our clinical trials centers around ABT (Diet Counseling). It’s been observed that subjects who do not receive ABT experience faster initial weight loss during the early stages of their weight loss regimen. However, their ability to maintain this weight loss in the long term is significantly lower compared to subjects who received ABT-Diet Therapy. This underscores a strong positive correlation between long-term weight loss success and DABT, regardless of whether subjects receive a placebo or GLP-1 agonist injections.

If you’re interested in gaining a deeper understanding of the current state of obesity and diabetes treatment, as well as the groundbreaking advances in these fields, please don’t hesitate to contact us at info@sosnutritionconsulting.com